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Abstract: The therapy of inflammatory bowel disease, particularly
with tumor necrosis factor (TNF) blockers, may be associated with a
number of cutaneous adverse effects, including psoriasis-like, eczema-
like, and lichenoid eruptions. Other rare skin complications are neu-
trophilic dermatoses such as amicrobial pustulosis of the folds (APF),
which is a chronic relapsing pustular disorder classified in this spectrum.
The authors analyzed clinical, histopathologic, and cytokine expres-
sion profiles of 3 inflammatory bowel disease patients with APF
triggered by adalimumab (patient 1) and infliximab (patients 2 and 3).
All 3 patients presented with sterile pustules involving the cutaneous
folds, genital regions, and scalp 6 months after starting adalimumab
(patient 1) and 9 months after starting infliximab (patients 2 and 3).
Histology was characterized by epidermal spongiform pustules with a
dermal neutrophilic and lymphocytic infiltrate. Tumor necrosis factor
blocker withdrawal associated with topical and systemic corticosteroids
induced complete remission of APF in all 3 patients. The expressions of
interleukin (IL)-1 beta and its receptors as well as TNF alpha and its
receptors were significantly higher in APF than in controls. Also IL-17,
leukocyte selectin, and chemokines, such as IL-8, [C-X-C motif]
chemokine ligand 1/2/3 (C¼ cysteine, X¼ any amino acid), [C-X-C
motif] chemokine ligand 16 (C¼ cysteine, X¼ any amino acid), and
RANTES (regulated on activation, normal T cell expressed and
secreted) were significantly overexpressed. Finally, the authors found
significant overexpression of both metalloproteinases 2/9 and their
inhibitors 1/2.
The observation of 3 patients with APF following anti-TNF therapy
expands not only the clinical context of APF but also the spectrum ofD, Emilio Berti, M etti, MD,
ugno, MD
(Medicine 94(45):e1818)
Abbreviations: APF = amicrobial pustulosis of the folds, BCA =
bicinchoninic acid, CD = Crohn disease, CXCL = [C-X-C motif]
chemokine ligand [C¼ cysteine, X¼ any amino acid], E-selectin =
endothelial selectin, IBD = inflammatory bowel disease, IFN =
interferon, IL = interleukin, IL-1R = interleukin-1 receptor, ITP =
idiopathic thrombocytopenic purpura, L-selectin = leukocyte
selectin, MMP = matrix metalloproteinase, PG = pyoderma
gangrenosum, RANTES = regulated on activation, normal T cell
expressed and secreted, RIPA = radioimmunoprecipitation assay,
SS = Sweet syndrome, TIMP = tissue inhibitor of metalloproteinase,
TNF = tumor necrosis factor, TNFR = tumor necrosis factor receptor,
UC = ulcerative colitis.
INTRODUCTION
I nflammatory bowel disease (IBD), including Crohn disease(CD) and ulcerative colitis (UC), may present extraintestinal
manifestations in up to 40% of cases.1 Among the extraintest-
inal organs, the skin is one of the most commonly affected.
Mucocutaneous findings are frequent and may occur in 22% to
75% of patients with CD2,3 and in 5% to 11% of patients with
UC.4 Skin manifestations associated with IBD are polymorphic
and can be classified into 4 categories according to their
pathophysiology: specific, reactive, associated, and induced
by IBD treatment.5 Cutaneous manifestations are regarded as
specific if they share with IBD the same granulomatous histo-
pathologic pattern: perianal or metastatic CD, commonly pre-
senting with abscesses or fistulas. Reactive cutaneous
manifestations are different from IBD in the histopathology
but have close physiopathologic links: autoinflammatory skin
diseases such as neutrophilic dermatoses are the paradigm of
this group. Among the cutaneous diseases associated with IBD,
the most commonly seen are erythema nodosum and psoriasis.
There are a number of cutaneous manifestations because of
adverse effects of IBD therapy, in particular biologics, includ-
ing psoriasis-like, eczema-like, and lichenoid eruptions as well
as cutaneous lupus erythematosus. These immune-mediated
inflammatory skin reactions represent a paradoxical event
considering that biologic agents, most notably anti-tumor necro-
sis factor (TNF), are commonly used in the management of
severe psoriasis. Autoinflammatory neutrophilic dermatoses
have been very rarely reported in IBD patients under TNF
blocker therapy;6 in particular, to the best of our knowledge,ial pustulosis-like rash in a patient with
ha has been described.7 Here, we studied
developed a paradoxical skin reaction
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manifesting as amicrobial pustulosis of the folds (APF) after
treatment with anti-TNF alpha agents [2 patients were treated
with infliximab (a chimeric mouse–human monoclonal anti-
TNF alpha antibody) and 1 with adalimumab (a fully human
monoclonal anti-TNF alpha antibody)]. Amicrobial pustulosis
of the folds is a chronic relapsing neutrophilic dermatosis that
presents with sterile pustular lesions involving the main
cutaneous folds, genital regions and scalp.8,9 Clinical, histo-
pathologic, and cytokine expression profiles of the 3 patients
have been analyzed. Notably, we have evaluated the main
proinflammatory cytokines and chemokines commonly
involved in autoinflammatory diseases with the aim of support-
ing the autoinflammatory nature of anti-TNF-induced APF in
IBD patients.
PATIENTS AND METHODS
Patients
Three patients attended our University Department from
2012 to 2015 for having developed a skin reaction to anti-TNF
agents manifesting as APF were studied clinicopathologically
and immunologically. The patients were followed-up for a
period ranging from 3 to 36 months. The diagnosis of APF
was established on the basis of criteria previously suggested by
Marzano et al9 and modified as reported in Table 1. To conduct
the immunologic study, lesional skin biopsies taken from the 3
patients were evaluated by means of a cytokine array method.
The controls were normal skin tissue specimens taken from 6
patients (4 women and 2 men; age range: 27–37 years) who
underwent excision of benign skin tumors (melanocytic nevi).
All the controls were not overweight nor had any cutaneous or
Marzano et alsystemic immune-mediated disorder. Blood and tissue samples
were collected during routine diagnostic procedures and al
patients gave oral informed consent that remaining samples
TABLE 1. Diagnostic Criteria for Amicrobial Pustulosis of the
Folds
Major Criteria Minor Criteria
Pustulosis involving 1 or
more major folds, 1 or
more minor folds, and the
anogenital area
Association with 1 or more
autoimmune or
autoinflammatory
disorders
Histologic pattern consisting
of intraepidermal
spongiform pustules and a
mainly neutrophilic
dermal infiltrate
Positive ANA at a titer of 1
160 or higher
Negative culture from
unopened pustule
One or more serum
autoantibodies (anti-ENA,
anti-dsDNA,
antiphospholipid,
antihistone, antismooth
muscle, antimitochondrial
antigastric parietal cell,
and antiendomysial)
The diagnosis of amicrobial pustulosis of the folds can be ascertained
if major criteria and at least 1 minor criterion are fulfilled.
ANA¼ antinuclear antibodies; dsDNA¼ double-stranded DNA
ENA¼ extractable nuclear antigens.
2 | www.md-journal.coml
/
,;could be used for research purposes. The protocol was approved
by the Institutional Review Board of IRCCS Fondazione Ca’
Granda, Ospedale Maggiore Policlinico, Milano, Italy.
Methods
Cytokine Array
Each tissue sample was weighed and diced into very small
pieces using a clean razor blade. Frozen tissues were sliced very
thinly and thawed in radioimmunoprecipitation assay buffer (sc-
24948) containing protease and phosphatase inhibitors by using
3mL of ice-cold radioimmunoprecipitation assay buffer per
gram of tissue.
Sampleswere incubated on ice for 30minutes, transferred to
microcentrifuge tubes and centrifuged at 10,000 g for 10
minutes at 4 8C. The supernatant was collected and the sample
was centrifuged again. The new supernatant fluid was added to
the previous one, thismixture representing the total cell lysate. To
standardize the cell lysate of each tissue sample, wemeasured the
total proteins in each sample by a micro bicinchoninic acid kit
(ThermoScientific,Waltham,MA). For each sample,we loaded a
volume containing 100mg of proteins in a glass slide format of
cytokine antibody array (RayBio1, Norcross, GA). The volume
to be loaded was calculated by the following formula: volume
(expressed in mL)¼ 100mg/protein concentration (expressed in
mg/mL). Each glass slide array contained 14 subarrays and was
suitable for 14 samples. Each subarray was allowed to evaluate
cytokine expression levels in a sample. Normalization of data at
the end of the experiment provided semiquantitative results. The
subarray was composed by specific antibodies against target
molecules coated on the glass slide. After the hybridization of
tissue lysate, each antibody bound its target molecule and
unbound proteins were washed out. The slidewas then incubated
with biotin-conjugated antibodies against the same target cyto-
kines, washed and then incubated with Cy3-conjugated strepta-
vidin, creating a biotin–streptavidin–Cy3 complex detectable
using a microarray laser scanner. By using data extraction soft-
ware, we could convert fluorescent signals into numerical data
and, after normalization, we obtained an expression value of
signal intensity for each molecule in each sample. The molecules
tested were the following: interleukin-1 beta (IL-1 beta), inter-
leukin 1 receptor I (IL-1RI), IL-1RII, TNF alpha, tumor necrosis
factor receptor I (TNFRI), TNFRII, IL-17, IL-17R, leukocyte
selectin (L-selectin), endothelial selectin, IL-8, regulated on
activation, normal T cell expressed and secreted (RANTES),
[C-X-C motif] chemokine ligand 1,2,3 (C¼ cysteine, X¼ any
amino acid) (CXCL 1,2,3), CXCL 16, matrix metalloproteinase
(MMP)-2,MMP-9, tissue inhibitor ofmetalloproteinase (TIMP)-
1, and TIMP-2.
Statistics
Because the signal intensity data were positively skewed,
they were log transformed before analysis. The results are
reported as antilog values of means with standard deviation.
Student t test for unpaired values was used to assess statistical
significance of differences. The significance level was set at
P<0.05.
RESULTS
Medicine  Volume 94, Number 45, November 2015Clinical Features
Clinical features are reported in Table 2. A 35-year-old
woman (patient 1) was referred for evaluation of a recurrent
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.pustular and erosive eruption of 6 month duration involving
mainly the inguinal folds and anogenital region. She had a 5-
year history of undifferentiated connective tissue disease and a
2-year history of Crohn disease (CD). For treating CD, she had
been receiving adalimumab subcutaneously for 1 year (induc-
tion dose of 160mg at week 0 and 80mg at week 2, followed by
a maintenance dose of 40mg every other week). She was
initially treated by the gastroenterologists with several courses
of systemic (amoxicillinþ clavulanic acid) and topical (mupir-
ocin) antibiotics without any improvement.
A 38-year-old man (patient 2) and a 26-year-old woman
(patient 3) were referred to our department for cutaneous
manifestations closely similar to those seen in patient 1, present
since 3 months. Both had a 6-year history of IBD, namely UC in
patient 2 and CD in patient 3. Both had been receiving infusions
of infliximab (5mg/kg) for 1 year every other month, following
an attack schedule of 1 infusion at time 0 and after 2 and 6
weeks. Also in these patients, previous antibiotic regimen had
failed to obtain any clinical response.
On examination, in all 3 patients, there were multiple
erythematous pustules (Fig. 1A) coalescing in macerated
erosive areas (Fig. 1B), symmetrically involving the major
skin folds, such as axillae and groins (Fig. 1C), and the
anogenital region (Fig. 1D) as well as minor folds, such as
the external auditory canals, retroauricular flexures (Fig. 2A-B),
and the area around the nostrils; the cutaneous lesions were
associated with intense oozing and accompanied by burning. In
patient 1, a large eroded plaque was also present in the inter-
gluteal fold (Fig. 2C). None of the patients was overweight.
Laboratory Findings
Results from laboratory examinations are shown in
Table 2. On admission to our department, the erythrocyte
sedimentation rate was elevated in all 3 patients (60, 100,
and 70mm/first hour, respectively); C-reactive protein was also
increased in all 3 patients (1.25, 6.2, and 4.1mg/dL, respect-
ively; normal values <0.5mg/dL). Patient 1 showed also mild
anemia (hemoglobin: 11.4 g/dL). Antinuclear antibodies, at a
titer of 1/320 with homogeneous pattern, were present in patient
1. In all 3 patients, serum zinc levels were within the normal
limits. Repeated bacteriological cultures from closed pustules
were negative, while cultures from erosive areas demonstrated
the presence of Staphylococcus aureus in all 3 patients. Fungal
cultures were negative in all 3 patients.
Histopatologic Aspects and Direct/Indirect
Immunofluorescence Findings
In all 3 patients, light microscopy studies of skin biopsy
specimens obtained from an affected area revealed a very similar
pattern characterized by spongiform pustules in the epidermis
with slight acanthosis and dermal edema with a mixed neutro-
philic and lymphocytic inflammatory infiltrate (Fig. 3).
Direct immunofluorescence, performed on peripustular
normal skin, was negative and indirect immunofluorescence
failed to detect circulating antibodies in any of the 3 cases
(except for antinuclear antibodies in patient 1).
Treatment and Course
Patient 1 was treated with both topical and systemic
corticosteroids (clobetasol dipropionate and intravenous
Skin Reaction to Tumor Necrosis Factor Blockersmethylprednisolone 1mg/kg/d, respectively), achieving rapid
improvement of the clinical picture. Considering the tendency
of APF lesions to relapse upon tapering the doses of
www.md-journal.com | 3
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Marzano et al Medicine  Volume 94, Number 45, November 2015methylprednisolone and based on the potential triggering role of
adalimumab, the patient, however, was switched to ustekinu-
mab for her CD. At the time of writing, after a follow-up period
of 3 months, there was complete resolution of the pustules and
marked improvement of the intergluteal plaque, which was
clinically diagnosed as metastatic CD (the patient refused a
skin biopsy on the latter site).
In patient 2, a pulsed therapy with intravenous methyl-
prednisolone 250mg/d for 3 days (followed by oral prednisone
at progressively tapering doses), in combination with switching
over to sulfasalazine for UC, induced complete healing of
cutaneous manifestations, lasting at the time of writing after
a follow-up of 18 months.
In patient 3, clearing of APF lesions was obtained using the
same treatment schedule as in patient 1, associatedwith switching
over to sulfasalazine as in patient 2. At the time of writing, on a
36-month follow-up, there was still complete remission of APF.
FIGURE 1. Clinical features of amicrobial pustulosis of the folds
pustules involving the axilla in patient 3. B, Erosive area because o
vegetating aspects on the inguinal fold in patient 2. D, ErythemaIn all 3 patients, systemic antibiotic therapy (amoxicil-
linþ clavulanic acid) in combination with antiseptic baths was
given to treat the S. aureus superinfection.
Expression Analysis of Cytokines, Chemokines,
and Effector Molecules in Skin Specimens
Cytokine Expression
Interleukin-1 beta and its receptors (IL-1RI and II) were
significantlymore expressed in lesional skin of the 3 patientswith
APF(20.75 48.96,4.33 2.79,and13.63 13.74,respectively)
4 | www.md-journal.comthan in normal skin (3.42 1.87, 2.00 0.82, and 4.49 1.73;
P¼ 0.023,P¼ 0.013, andP¼ 0.027, respectively; Figure 4). The
proinflammatory cytokine TNF alpha was also overexpressed
(3.85 0.74versus2.60 0.19;P¼ 0.003)aswell as its receptors
TNFRI (14.74 2.74 versus 5.87 3.43;P¼ 0.005) andTNFRII
(15.89 4.09versus6.25 3.31;P¼ 0.017;Figure5).Finally,we
observed an overproduction of IL-17 (6.09 4.70 versus
2.17 0.44; P¼ 0.014) and its receptor IL-17R (6.68 0.55
versus 3.98 1.33; P¼ 0.026, Figure 6).
Leukocyte Selectin Expression
The expression of L-selectin was significantly higher in
lesional skin of the 3 patients with APF (10.32 6.76) than in
normal skin (2.14 1.21; P¼ 0.005; Figure 6).
Chemokine Expression
As compared with controls, lesional skin of APF
patients showed overexpression of chemokines promoting
neutrophil transendothelial migration into inflamed tissues,
such as IL-8 (12.53 8.65 versus 2.73 1.05; P¼ 0.003),
CXCL 1/2/3 (109.70 108.58 versus 7.61 7.75;
P¼ 0.001), CXCL 16 (4.40 0.54 versus 2.50 0.74;
P¼ 0.007), and RANTES (19.74 19.65 versus
3.41 1.57; P¼ 0.004; Figure 7).
Matrix Metalloproteinase and Tissue Inhibitor of
gered by tumor necrosis factor alpha blockers. A, Erythematous
oalescence of pustules on the axilla in patient 3. C, Erosions with
s erosive lesions on the anogenital region in patient 1.Metalloproteinase Expression
In lesional skin of APF patients, we observed a significant
overexpression of molecules involved in tissue damage, such
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 2. Clinical features of amicrobial pustulosis of the folds triggered by tumor necrosis factor alpha blockers. Macerated erosive
lesions with crusts on the retroauricular region in patient 2 (A) and in patient 3 (B). C, Erythematous plaque surrounded by an exudating
erosive area on the intergluteal region in patient 1.
FIGURE 3. Histopathologic features of amicrobial pustulosis of the folds triggered by tumor necrosis factor alpha blockers. The histology
shows pustules (highlighted with arrows) and a mainly neutrophilic infiltrate in the epidermis as well as a predominantly lymphocytic
infiltrate in the upper dermis (hematoxylin and eosin stain; original magnification, 200).
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FIGURE 4. Expression of IL-1 beta and its soluble receptors I and II in homogenate samples of lesional skin from 3 patients with amicrobial
ers
Marzano et al Medicine  Volume 94, Number 45, November 2015as MMP-2 (6.96 3.24 versus 2.49 0.90; P¼ 0.008) and
MMP-9 (388.69 54.56 versus 24.71 68.33; P¼ 0.0001;
Figure 8). Overproduction of molecules responsible for inhibi-
tory signals aimed at attenuatingMMP-mediated inflammation
was also demonstrated: TIMP-1 (47.02 83.04 versus
pustulosis of the folds triggered by tumor necrosis factor alpha block
signal intensity in a cytokine array assay.4.45 1.63; P¼ 0.004) and TIMP-2 (107.45 111.29 versus
48.69 24.40), the latter, however, did not reach statistical
significance (Figure 8).
DISCUSSION
Amicrobial pustulosis of the folds is a rare chronic relap-sing dermatosis that affects almost exclusively young women
with sudden onset of follicular and nonfollicular sterile pustular
lesions involving the main cutaneous folds, anogenital area and
FIGURE 5. Expression of tumor necrosis factor alpha and its soluble
patients with amicrobial pustulosis of the folds triggered by tumor nec
Numerical values represent signal intensity in a cytokine array assay.
6 | www.md-journal.comscalp as well as minor skin folds, particularly the area around the
nostrils, retroauricular regions, and external auditory canals.
The clinical picture of APF is similar to that of the inverse type
of psoriasis pustulosa, which, however, usually spares the minor
folds and often presents with psoriasis lesions in other sites of
the body. Its histologic picture is characterized by subcorneal
pustules associated with a mainly neutrophilic infiltrate in the
dermis, which led to include APF in the spectrum of neutro-
philic dermatoses.9 Neutrophilic dermatoses represent a clini-
cally heterogeneous group of disorders hallmarked by an
accumulation of neutrophils in the skin and rarely internal
organs.10 Amicrobial pustulosis of the folds has been reported
. Six normal subjects served as controls. Numerical values representto be associated with a number of autoimmune diseases, includ-
ing lupus erythematosus,9,11 mixed connective tissue dis-
ease,12,13 myasthenia gravis,11 Sjo¨gren syndrome,14 celiac
receptors I and II in homogenate samples of lesional skin from 3
rosis factor alpha blockers. Six normal subjects served as controls.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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purpura,11 and immunoglobulin A nephropathy.16 It is well
known that neutrophilic dermatoses, particularly pyoderma
FIGURE 6. Expression of interleukin-17, its soluble receptor, and leu
with amicrobial pustulosis of the folds triggered by tumor necrosis f
values represent signal intensity in a cytokine array assay.gangrenosum (PG) and Sweet syndrome (SS), are among the
better recognized extraintestinal manifestations of IBD17 and in
2011, Lee et al7 described the first case of APF associated with
FIGURE 7. Expression of interleukin-8, regulated on activation, norm
1,2,3 (C¼ cysteine, X¼ any amino acid), and [C-X-C motif] chemok
samples of lesional skin from 3 patients with amicrobial pustulosis of the
subjects served as controls. Numerical values represent signal intensi
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.IBD. Here, we report 3 additional cases of APF in patients with
IBD treated with anti-TNF alpha agents. Although APF may
complicate IBD and other immune-mediated disorders at any
yte selectin in homogenate samples of lesional skin from 3 patients
r alpha blockers. Six normal subjects served as controls. Numericaltime during the disease course, in our patients, the strict
association of APF with TNF blocker therapy and its prompt
resolution upon drug withdrawal support the triggering role of
al T cell expressed and secreted, [C-X-C motif] chemokine ligand
ine ligand 16 (C¼ cysteine, X¼ any amino acid) in homogenate
folds triggered by tumor necrosis factor alpha blockers. Six normal
ty in a cytokine array assay.
www.md-journal.com | 7
FIGURE 8. Expression of matrix metalloproteinase-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase 1, and tissue
inhibitor of metalloproteinase 2 in homogenate samples of lesional skin from 3 patients with amicrobial pustulosis of the folds triggered by
on
Marzano et al Medicine  Volume 94, Number 45, November 2015anti-TNF treatment. Tumor necrosis factor blockers are respon-
sible for a number of cutaneous adverse reactions, the most
frequent of which are pustular eruptions.6 Pustular reactions
represent a paradoxical event because TNF antagonists are
commonly used in the treatment of psoriasis, including its
pustular variant. Pustular psoriasis and other neutrophilic der-
matoses, such as PG and SS are nowadays considered autoin-
flammatory conditions, which are characterized by recurrent
episodes of sterile inflammation, without circulating autoanti-
bodies and autoreactive T cells.17 Increasing evidence, how-
ever, supports clinical and immunologic similarities between
autoimmune and autoinflammatory diseases, giving rise to
consider them as a single group of diseases with a large
spectrum of immunologic and clinical abnormalities, which
include at 1 end pure autoinflammatory diseases and at the other
end pure autoimmune diseases.18 In PG and SS, we recently
demonstrated an overexpression of cytokines/chemokines and
molecules amplifying the inflammatory network, supporting the
view that these disorders are autoinflammatory in origin.19
In our study, we found an overexpression of IL-1 beta and
its receptors in all 3 patients. This could be linked to dysregula-
tion of the function of inflammasome, which is a molecular
platform responsible for the activation of caspase 1, an enzyme
inducing the proteolytic cleavage of the inactive pro-IL-1 beta
to its functionally active form, IL-1 beta. Interleukin-1 promotes
the production and release of both classic proinflammatory
tumor necrosis factor alpha blockers. Six normal subjects served as c
assay.cytokines, such as TNF alpha and interferon gamma, and a
number of chemokines, notably IL-8 and RANTES.20 Tumor
necrosis factor alpha, which also acts as a key regulator of other
8 | www.md-journal.comproinflammatory cytokines and chemokines, including the same
IL-1 beta and IL-8,21 was overexpressed in all the 3 APF
patients. Also chemokines, such as IL-8, CXCL 1/2/3, CXCL
16, and RANTES, were overexpressed, promoting neutrophil
transendothelial migration into the site of inflammatory process
that was also favored by the upregulation of L-selectin. In our
study, we found an overexpression of IL-17 and its receptor in
all 3 patients, confirming the previously hypothesized role for
this T-helper 17-related cytokine in the pathophysiology of the
whole spectrum of neutrophilic dermatoses, similarly to psor-
iasis and other autoimmune diseases.22–24 Interleukin-17 ampli-
fies the recruitment of neutrophils and monocytes by increasing
the local production of chemokines, most notably IL-825 and
synergizing with various other cytokines, in particular with TNF
alpha.26 Moreover, IL-17, such as IL-1 and TNF alpha, induces
the production of MMPs,27 a family of endopeptidases that
include the so-called gelatinases MMP-2 and MMP-9. An
improper activity of MMPs synthesized by inflammatory cells,
particularly neutrophils, is known to cause tissue damage via
degradation of components of the extracellular matrix and to
influence the production of chemokines, promoting neutrophil
transendothelial migration.28
Here, we found an overexpression of MMP-9 in the skin
inflammatory infiltrate, suggesting that this proteinase and to a
lesser degree MMP-2 may be involved in inducing tissue
damage. Interestingly, we detected also an overproduction of
trols. Numerical values represent signal intensity in a cytokine arrayTIMP-1 and TIMP-2, which likely represent an inhibitory
pathway aimed at attenuating the MMP-mediated inflam-
mation.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
The main limitation of our study is the small number of
patients, because of the rarity of drug-induced APF, which
may be, however, counterbalanced by the wide panel of
molecules investigated and by the clear-cut differences
observed. One could argue that the ideal controls to evaluate
the role of proinflammatory cytokines in the pathogenesis of
anti-TNF-induced APF would be samples taken from normal
skin of IBD patients and/or nonlesional skin of patients with
anti-TNF-induced APF. We, however, have decided to
choose normal skin of patients without any immune-mediated
disorder as control to avoid the possible finding of an initial
low overexpression of inflammatory effector molecules pre-
ceding the development of cutaneous lesions; on the contrary,
a strong expression of proinflammatory cytokines is unlikely
in the absence of cutaneous lesions, as previously found in
other neutrophilic dermatoses, such as PG and SS.19 Another
source of bias could be the location of the biopsy because the
skin of areas different from major and minor folds is not
involved in APF. Testing the normal skin of major and minor
folds in IBD patients before and after treatment with
TNF-blockers could be matter for future studies aimed at
identifying early molecular markers predicting the onset of
skin–drug reactions.
Overall, our data show high values of proinflammatory
cytokines, chemokines, and tissue damage effector molecules,
supporting the autoinflammatory origin of APF as paradoxical
skin reaction to TNF blockers. Concerning a possible expla-
nation of this paradoxical side effect, it is possible to hypoth-
esize pathomechanisms similar to those of the psoriatic skin
lesions occurring in the setting of anti-TNF therapy, which are
mainly related to uncontrolled increase of IFN alpha as a result
of TNF pathway blockade.29,30 The activation of autoreactive T
cells,31,32 certain infectious agents,31,33 and a genetic suscepti-
bility31,33,34 could be possible further mechanisms.
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